research_overview

Research Overview

Neuropsychiatric disorders, and behavioral issues that impact on medical treatment, have a big impact on quality of life and often on mortality as well. Research that improves our treatment and understanding of these problems is an important part of improving public health. The Department of Psychiatry and Health Behavior has expanded its research effort substantially in recent years. Research is being conducted in several areas at MCGHI and Veterans Administration sites. External research funding has steadily increased from about $1.5 million in 2001-2002 to $4.5 million in 2004-2005. This funding comes from the National Institutes of Health (NIH), foundations, intramural MCG awards, and other sources. Department members also serve on grant review committees for NIH and the Veterans Administration.

Several studies focus on the neurobiology and treatment of affective disorders. In a pharmacogenetic study, Dr. Adriana Foster is collaborating with members of the Pathology Department to test a new method for identifying patients who metabolize antidepressants at an abnormal rate. This approach may help individualize treatment in the future. Trials of novel antidepressants are being conducted by Dr. Henry Hobby. Lithium treatment is also under investigation by Dr. Gowdha. Dr. Simon Sebastian is studying the sleep disturbance in bipolar disorder.

Research in psychosis includes several funded trials, most involving antipsychotics. Premarketing as well as postmarketing studies are underway. In a study by Dr. Peter Buckley that is competitively funded by the National Institute of Mental Health, a new formulation of the antipychotic drug risperidone is being compared to other antipsychotics. Laboratory studies of oxidation and fatty acids in animals provide the basis for a clinical trial of fatty acids and antioxidants as adjunctive treatments for schizophrenia. Non-treatment studies of psychotic disorders are also underway. One study headed by Dr. Brian Kirkpatrick, which is funded by the National Institute of Diabetes and Digestive and Kidney Diseases, examines the risk for diabetes in people with schizophrenia who have never taken antipsychotic drugs. Other work focuses on the genetics of schizophrenia, and on non-genetic risk factors. A shortened telomere is a predictor of mortality in the general population; the telomere is a non-coding structure on the chromosome. Department researchers have found that schizophrenia is associated with a shortened telomere, which may be related to the increased mortality associated with schizophrenia.

The Department also has a number of studies in behavioral medicine. Dr. John Arena is studying biofeedback, while Dr. Lara Stepleman is investigating the recognition and treatment of depression in primary care and in multiple sclerosis. Research by Dr. Amy House on women’s health focuses on the effects of traumatic stress on physical and mental health.

Several mental health problems in children and adolescents are under investigation. The results of Dr. Donna Londino suggest that use of antipsychotics may be an effective

treatment for Asperger’s syndrome. Dr. Londino is also conducting a spectroscopy study of Asperger’s syndrome; this study may point to other novel treatment approaches. Dr. Sandra Sexson is directing a study of EEG in attention-deficit/hyperactivity disorder. Family interventions to prevent recidivism in juvenile criminal offenders are being investigated by Dr. Bernard Davidson. Dr. Nick Patel, an investigator in the School of Pharmacy, is involved in several drug trials in children and adolescents in collaboration with members of our Department.

Eating disorders are an important cause of morbidity and are associated with an increased mortality. Dr. Christian Lemmon is involved in several studies of eating behavior and eating disorders, working with both the Georgia Prevention Institute and Dr. Patel.

Several basic scientists also hold joint appointments in Psychiatry, and several translational clinical projects are underway. Dr. Sahebarao Mahadik is studying neurotrophic factors and oxidation/reduction abnormalities in schizophrenia. Dr. Anilkumar Pillai is studying neurotrophic factors as possible factors for the development of novel treatments for psychosis. Drs. Alvin Terry (cholinergic mechanisms and antipsychotics), Lin Mei (neuregulin1 and ErbB receptors), Clare Bergson (calcyon), and Almira Vazdarjanova (plasticity) are other basic scientists with close ties to the Department who are interested in translational work related to schizophrenia.

MCG is pursuing a federally funded Clinical and Translational Science Awards (CTSA). These awards, which are a major initiative of the National Institutes of the national Institutes of Health, provide funding for research infrastructure for campus-wide use. MCG will apply for a CTSA in a consortium with the University of South Carolina and the Medical University of south Carolina. As part of this effort, the Department has come into more contact with the Psychiatry Departments at the two other schools, and these relationships are likely to strengthen over time. The director of the CTSA will be Dr. Kathleen Brady, a psychiatrist at MUSC.

The Department has also developed a number of other local, national and international collaborations. Active collaborations are being conducted nationally, as well as in Spain, Italy, and Finland.

The increased emphasis on research is reflected by the activities of the Department’s trainees. Several medical students have worked with faculty members on research projects. Residents have also published papers in competitive journals and won regional and national research and travel awards. A research fellowship in psychotic disorders is also available.

The ability to compete successfully for external funding is an important measure of the quality of biomedical research. In fiscal year 2007, the Department had a total of $468,353 in Federal grants, $3,704,963 from pharmaceutical companies, and $920,595 in other grants, for a total of $5,093,911.

FACULTY RESEARCH INTERESTS

Schizophrenia and Mood Disorder Program
Peter F. Buckley, M.D. Clinical trials of antipsychotics Neurotrophic factors as clinical tools in the treatment of psychotic disorders
Denise Evans, M.D. Evaluation of a cross-section of patients on various antipsychotics for augmentation, essential fatty acids, and antioxidants
Adriana Foster, Ph.D. Treatment trials focusing on: Metabolic problems in schizophrenia associated with antipsychotics Relapse prevention in schizophrenia The treatment of cognitive impairment in schizophrenia
Henry Hobby, M.D. Clinical trials of novel antidepressants
Brian Kirkpatrick, M.D., M.S.P.H. Genetics of schizophrenia Mortality in schizophrenia Schizophrenia as a syndrome of accelerated aging Non-genetic risk factors for schizophrenia Negative symptoms
Sahebarao Mahadik, Ph.D. Oxidative stress markers and essential fatty acids in schizophrenia, their relationship to treatment outcome Preclinical studies of possible neuroprotective treatment strategies for schizophrenia Neurotrophins in schizophrenia and its treatment
Carmen Nichita, M.D. Psychotic vs. nonpsychotic murder defendants referred for pretrial evaluation Informed consent with mood stabilizing drugs
Anilkumar Pillai, Ph.D. Cellular and molecular mechanisms of neurotrophin signaling in schizophrenia Preclinical studies of neurotrophic factors as targets for the development of novel treatment strategies in schizophrenia
Simon Sebastian, M.D. Transcranial magnetic stimulation in Parkinson's disease and schizophrenia Drug trials of antipsychotics Drug trials of cognition-enhancing drugs in schizophrenia
Health Behavior
Bernard Davidson, Ph.D. Impact of family therapy on recidivism in juvenile offenders
Rebecca Jump, Ph.D. Psychosocial factors, history of trauma and health outcomes in Sickle Cell Disease Cognitive Dialectical Behavior Therapy for Chronic Pain Group Therapy
Alex Mabe, Ph.D. The process of recovery in serious mental illness Development of recovery educational tools
Erick Messias, M.D., Ph.D. Asthma and suicide Epidemiological studies of the interaction of psychological and physical health
Child and Adolescent Psychiatry
Donna Londino, M.D. Clinical trials in Asperger's syndrome Spectroscopy in Asperger's syndrome EEG in the evaluation of attention deficit/hyperactivity disorder

RESEARCH BY TRAINEES

Psychiatry and psychology are also involved in research. The MCG class of 2007 psychology residents published 3 papers and two abstracts during their year of training, and submitted another paper for publication. They made six presentations at regional and national meetings.

The new educational efforts in the psychiatry residency on how to be an intelligent consumer of research results are covered elsewhere. The residency’s required academic project is an important introduction to the practicalities of research.
Psychiatry residents are also taking advantage of research opportunities in the Department (see the publication and presentation lists). Residents in the General program and in the Child and Adolescent program had eight publications and eight presentations at meetings during the 2006-2007 academic year.

The increasing strength of the research opportunities in the psychiatry residency are reflected in the recent results of the competition for the Georgia Psychiatry Physicians Association’s Joe & Hope Skobba Memorial Award. MCG residents won first, second, and third prizes! In 2006, they won first prize. A second-year resident, Dr. Brian Miller, was invited to the APA Research Colloquium for Junior Investigators.

PUBLICATIONS

Bahmiller D, Kenna CA, Shevitz SA, Buckley, P. Mental Health Transformation: Resident Education and Perceptions of Recovery. Submitted for publication.

Barbeau, P., Johnson, M.H., Howe, C.A., Allison, J., Davis, C.L., Gutin, B., & Lemmon, C.R. MCG Exercise Project: Changes in body composition, visceral adiposity, and fitness in young black girls. Obesity. (In Press)

Buckley PF, Fenley G, Mabe A, Peeples S. Recovery and schizophrenia. Clinical Schizophrenia and Related Psychoses 2007; 1: 96-100.

Buckley PF, Foster A. Quetiapine. In: A textbook of psychopharmacology, Schatzberg AF, Nemeroff CB (editors), American Psychiatric Association (in press).

Buckley PF, Kenna C, Bahmiller D, Powell I, Shevitz S, Fricks L. Resident education and recovery: Observations and commentary. Academic Psychiatry (2007, in press).

Buckley PF, Loebel A, Harvey PD. Recovery and remission in schizophrenia. Schizophrenia Research (2007, in press).

Buckley PF, Mahadik SP, Khan M, Evans DR. Leptin levels in first episode schizophrenia. Neuropsychopharmacology (submitted for publication)

Buckley PF, Mahadik SP, Pillai A, Terry AV Jr. Neurotrophins and schizophrenia. Schizophrenia Research (in press)

Buckley PF, Messias E. Schizophrenia: A complex disease necessitating complex care. Psychiatric Clinics of North America (2007).

Buckley PF, Paulson B, Brecher M. Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine. Journal of Affective Disorders (2007, in press).

Buckley PF, Pillai A, Evans D, Stirewalt E, Mahadik SP. Brain Derived Neurotrophic Factor in First - Episode Psychosis. Schizophrenia Research 2007 91(1-3):1-5

Buckley PF, Sebastian S. Aripiprazole: an appraisal of the translation of complex receptor effects into clinical outcomes. Therapy 2005; 2(5):699-707.

Buckley PF, Stahl SM. Negative symptoms of schizophrenia: opportunity or therapeutic cul-de-sac? Acta Scandinavica Psychiatrica 2007;115:93-100.

Buckley PF. Professional Development. In: Administrative Psychiatry. Wilson DR, Buckley PF. Psychiatric Clinics of North America (in press).

Buckley PF. Reflections on leadership as chair of a department of psychiatry. Academic Psychiatry 2006; 30:309-314.

Buckley PF. The bipolar spectrum: critical diagnosis. Clinical Psychiatry News 2005; 53-55.

Buckley PF. The neuropharmacology of switching antipsychotic medications. Journal of Clinical Psychiatry (2007, in press).

Buckley PF. Which antipsychotic do I choose now? CATIE 2 offers insight on efficacy, tolerability. Current Psychiatry 2006; 5:27-43.

Buckley PF, Sebastian S. Aripiprazole: an appraisal of the translation of complex receptor effects into clinical outcomes. Therapy, Sep 2005, Vol. 2, No. 5, Pages 699-707.

Buckley PF, Meinsles L. The history of the American Association of Chairs of Departments of Psychiatry. Academic Psychiatry 2007; 31(2): 97-98.

Buckley, PF. Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. Journal of Clinical Psychiatry 2006; 67: 5-9.

C. Cusin, A. Serretti, J.L. Rausch, B. Bondy, E. Smeraldi. Pooling Pharmacogenetic Studies on Serotonin Transporter: A Mega-Analysis. Psychiatry Research. Nov 29;145(1):61-5, 2006.

Caldwell, C.L., Horne, A.M., Davidson, B., and Quinn, W. H. Effectiveness of a Multiple Family Group Intervention for Juvenile First Offenders in Reducing Parent Stress. Journal of Child and Family Studies, (Online First, DOI 10.1007/s10826-006-9097-y , December 20, 2007), paginated printed journal copy, scheduled June 2007.

Cohen AS, Saperstein AM, Gold JM, Kirkpatrick B, Carpenter WT Jr, Buchanan RW. Neuropsychology of the deficit syndrome: New data and meta-analysis of findings to date. Schizophrenia Bulletin, in press.

Crismon L, Buckley PF. Schizophrenia. In: Pharmacotherapy: a pathophysiological approach, Seventh Edition. Edited bu Depiro J, Talbert RL, Yee GL, Matzke GR, Wells BG, Posey LM. McCraw-Hill. New York (2007, in press).

Foster A, Buckley PF. Schizophrenia. In: Conn’s Textbook of Medicine. McGraw-Hill (2007).

Foster A, Miller DD, Buckley PF. Pharmacogenetics of schizophrenia. In: Schizophrenia: a complex disorder necessitating comprehensive care. Buckley PF, Messias E (editors) Psychiatric Clinics of North America (2007; in press).

Foster A, Uzman M, Buckley FP. Pharmacogenetics and antipsychotic therapy. Neuropsychiatric disease and treatment (submitted for publication).
Foster A, Uzman M, Buckley PF. Schizophrenia: neurobiology. Current Psychiatry Reports (2007, in press).

Ginsberg DL, Schooler NR, Buckley PF, Harvey PD, Weiden PJ. Optimizing treatment for schizophrenia: enhancing affective/cognitive and depressive functioning. CNS Spectrum 2005; 10(2):1-15.

House A. S., Gillies, R.A., London, J.P., Jr. Trauma and women's health: From a psychobiological perspective. MedEdPORTAL; 2006. Available from: http://www.aamc.org/mededportal, ID = 481.

House, A. S. Increasing the usability of cognitive processing therapy for survivors of childhood sexual abuse. Journal of Child Sexual Abuse, 15(1), 87-103. (2006).

House, A. S. & Stepleman, L. M. (2006). From the Ground up: Building a Psychology of Women Internship Track. Professional Psychology: Research and Practice. 37, 423-429.

House, A. S., & Albritton, J Personality Disorder. In S. Loue & M. Sajatovic (Eds.) The Encyclopedia of Women's Health. New York: Kluwer Academic/Plenum, In press.

J.L. Rausch, E. Sirota, D. Londino, M. Johnson, R. Bhatia, S. Miller. Asperger’s Disorder and Negative Symptoms: An Open Trial of Risperidone. Journal of Clinical Psychiatry, Dec;66(12):1592-7, 2005.

J.L. Rausch, M.E. Johnson, K. M. Corley, J. Li, J. Hutcheson and J. Smith. “Serotonin transport kinetics correlated between human platelets and human brain synaptosomes”. Psychopharmacology, July;180(3):391-8, 2005.

J.L. Rausch. Initial Conditions of Psychotropic Drug Response: Studies of Serotonin Transporter Long Promotor Region (5-HTTLPR), Serotonin transporter (SERT) efficiency, cytokine and kinase gene expression relevant to depression and antidepressant outcome. Progress in Neuropsychopharmacology and Biological Psychiatry, July 29(6):1046-61, 2005.

Jones P, Buckley PF. In Clinical Practice: Schizophrenia. Elsevier (2006).
Kirkpatrick B, Hack GD, Higginbottom E, Hoffacker D, Fernandez-Egea E. Palate and dentition in schizophrenia. Schizophrenia Research 2007 Mar; 91(1-3):187-91.

Kirkpatrick B, Xu L, Cascella N, Ozeki Y, Roberts RC, Sawa A. DISC1 immunoreactivity at the light and ultrastructural level in the human neocortex. Journal of Comparative Neurology 2006 Jul 20;497(3):436-50.

Lemmon, C. R. Eating Disorders (Anorexia Nervosa, Bulimia Nervosa, Binge Eating Disorder) Ed. C.D. Berdanier. In: Handbook of Nutrition and Food 2nd edition. CRC Press, New York, NY – book chapter (in press).

Lemmon, C. R. & Barbeau, P. Bariatric Surgery for the Obese Patient: Important Psychological Considerations. In: Handbook of Nutrition and Food 2nd edition. Ed. C.D. Berdanier. In: Handbook of Nutrition and Food 2nd edition. CRC Press, New York, NY – book chapter (in press).

Lemmon, C.R., Ludwig, D.A., Howe, C., Smith-Ferguson, A., & Barbeau, P. Correlates of Adherence to a Physical Activity Program in Young African-American Girls. Obesity. (In Press).

Lester K, & Stepleman LM. (in press) Illness Severity, Perceived Illness Management, and Self-Reported Cognitive Impairment as Predictors of Depression and Anxiety in a Multiple Sclerosis Clinic Population. Journal of Behavioral Medicine.

Lindenmayer JP, Harvey PD, Khan A, Kirkpatrick B. Schizophrenia: Measurements of Psychopathology. In press, Psychiatric Clinics of North America.

Lindenmayer JP, Liv-Sevfert W, Kulkarni PM, Kinon B, Stauffer G, Edwards S, Chen L, Adams DH, Buckley PF, Citrome L. Volavka J. Medication nonadherence and treatment outcome in acutely in patients with schizophrenia of schizoaffective disorders with suboptimal prior response. Journal of Clinical Psychiatry (submitted for publication).

Mahadik SP, Pillai A. Comparison of Typical versus Atypical Antipsychotic Drugs: 5a. Effects of Sub-chronic and Long-term Treatment on Neurotrophic Factors and Neurogenesis. Brain Research Reviews, in press.

Mahadik SP, Buckley PF. Psychotropic agents, oxidative stress, and schizophrenia. In: Fatty acids and oxidative stress in neuropsychiatric disorders. Reddy N, Yao I, editors (2007, in press).

Mahadik SP, Evans D, Shendarkar N, Narasimhan M, Buckley PF. Can augmentation with omega-3 fatty acids and antioxidant supplementation enhance antipsychotic treatment response in schizophrenia? In: Fatty acids and oxidative stress in neuropsychiatric disorders. Reddy N, Yao I, editors, (2007, in press).

Mahadik SP, Pillai A, Joshi S, Foster A. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int Rev Psychiatry. 2006 Apr; 18(2):119-31.

Manne, S, DuHamel, K, Ostroff, J, Parsons, S, Martini, R, Williams, S, Mee, L, Sexson, S, Austin, J, Winkel, G, & Redd, W. Coping and the Course of Maternal Distress after Pediatric HSCT, Journal of the American Academy of Child and Adolescent Psychiatry, in press.

Matorin A, Guynn R, Sexson S, Kapoot V, Ruiz, P. Current and future psychotherapy trends in United States graduate psychiatric training Rivista di psichiatria, 40:1, 26-30.

Mehendale S., A Kilari, S Joshi, K Dangat, M Hegde, S Bapat, G Wagh, T Panchanadikar, M Bhapkar, A Gupta, V Taralekar, S Mahadik Increased oxidative stress, decreased antioxidants and altered fatty acid profile - causative factors in pre-eclampsia. British Journal of Obstetrics and Gynecology, revised submitted.

Messias ELM, Mourao C, Soerio Maia J, de Queiroz mendes Campos JP, gomes Ribeiro K, Alves Ribeiro L, Kirkpatrick B. Season of birth and schizophrenia in Northeast Brazil: relationship to rainfall. Journal of Nervous and Mental Disease 2006 Nov;194(11):870-3.

Mucci A, Galderisi S, Kirkpatrick B, Bucci P, Volpe U, Merlotti E, Centanaro F, Catapano F, Maj M. Double dissociation of N1 and P3 abnormalities in deficit and nondeficit schizophrenia. Schizophr Res. 2007 May;92(1-3):252-61.

Narasimhan M, Buckley PF. Predictors of treatment response in bipolar disorder. Current Advances in Bipolar Disorders 2006;5:36-44.

Nichita C, Buckley PF. Comorbidities of antisocial personality disorder. In: International Handbook of Psychopathy. Felthous A, Taylor P (editors) (in press).

Nichita C, Buckley PF. Management of aggression. In: Forensic Psychiatry. Taylor P (editor), (in press).

Peebles, S. A., Mabe, P. A., Davidson, L., Fricks, L., Buckley, P., & Fenley, G. Recovery and systems transformation for schizophrenia. Psychiatric Clinics of North America, Schizophrenia Issue. (in press, 2007).

Peeples S, Davidson L. Mabe A, Fenley G, Buckley PF. Recovery and schizophrenia. In: Schizophrenia: a complex disorder necessitating comprehensive care. Buckley PF, Messias E (editors) Psychiatric Clinics of North America (2007; in press).

Pillai A, Mahadik SP. Differential temporal effects of Haloperidol and Olanzapine on levels of vascular endothelial growth factor and angiogenesis in rat hippocampus. Schizophrenia Research, 87(1-3):48-59.

Pillai A, Mahadik SP. Differential temporal effects of Haloperidol and Olanzapine on Erythropoietin and its receptor in adult rat hippocampus and striatum. J Neurochemistry, 98(5):1411-1422.

Pillai A, Parikh V, Terry AV Jr, Mahadik SP. Long-term antipsychotic treatments and crossover studies in rats: Differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatric Res. 37: 43-51, 2006.

Pillai A, Terry AV Jr, Mahadik SP. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res. 2006; 82(1):95-106.

Rabineau, K.M., Mabe, P.A., & Vega, R.A. Parenting Stress in Pediatric Oncology Populations. (Submitted).

Rao S., Joshi S, Kale A, Hegde M., Mahadik S. (2006) Maternal folic acid supplementation to dams on marginal protein level alters brain fatty acid levels of their adult offspring. Metabolism: Clinical and Experimental (US) 55: 628-634.

Rausch JL, Johnson,ME, Kasik,K, Stahl,SM. Temperature Regulation in Depression: Functional 5HT1A Receptor Adaptation Differentiates Antidepressant Response. Neuropsychopharmacology. Oct;31(10):2274-80, 2006.

Rogers, L. Q., Gutin, B., Humphries, M, Lemmon, C. R., Waller, J. L., Baranowski, T, & Saunders, R. Evaluation of internal medicine residents as exercise role models and associations with self-reported counseling behavior, confidence, and perceived success. Teaching and Learning in Medicine, 18, 215-221 (2006).

Sebastian S. Mental Retardation. eMedicine Journal [serial online]. 2006.
Shelton, S.F. & Mabe, P.A. Spiritual Coping Among Chronically Ill Children. In SD Ambrose (Editor) Religion and Psychology: New Research.

Hauppauge, NY: Nova Science Publishers, Inc. pp. 53-71.(2006)
Smith D, Buckley PF. Clinical and forensic considerations on the treatment of delusional disorders. Behavioral Sciences and the Law 2006: 24:351-367.

Stahl SM, Buckley PF. Negative symptoms in schizophrenia: a problem that will not go away. Acta Psychiatrica Scandinavica 2007;115:4-11.

Stepleman, L. M., Hann*, G., Santos*, M. & House, A. S. (2006). Reaching Underserved HIV-Positive Individuals Using Patient-Centered Psychological Consultation. Professional Psychology: Research & Practice. 37(1), Feb 2006, 75-82.

Terry Jr AV, Gearhart DA, Mahadik SP, Warsi S. and Waller JL. Chronic exposure to typical or atypical antipsychotics in rodents: effects on high affinity nicotinic and muscarinic receptors in the brain. Neuroscience 140: 1277-1287, 2006.

Terry Jr AV, Gearhart DA, Warner S., Zhang G, Bartlett MG, Middlemore M-L., Beck WD, Mahadik SP, and Waller JL. Oral Haloperidol or Risperidone Treatment in Rats: Temporal Effects on Nerve Growth Factor Receptors, Cholinergic Neurons, and Memory Performance. Neuroscience in press.

Terry Jr AV, Parikh V, Gearhart DA, Pillai A, Hohanadel E, Warner S, Nasrallah HA, Mahadik SP. Time Dependent Effects of Haloperidol and Ziprasidone on Nerve Growth Factor, Cholinergic Neurons, and Spatial Learning in Rats. J Pharmacol Exp Ther. 318(2):709-724, 2006.

Terry, AV and Mahadik SP. Time-Dependent Cognitive Deficits Associated with First and Second Generation Antipsychotics: Cholinergic Deregulation as a Potential Mechanism: Perspective in Pharmacology in J. Pharmacol Exp Ther. 320:961-968, 2007.

Volarva J, Kinon B, Adams D, Citrome L, Stauffer G, LindenMayer JP, Meltzer HY, Edwards S, Buckley PF, Lieberman JA. A comparative trial of moderate versus high dose treatments of olanzapine in patients with schizophrenia. Journal of Clinical Psychiatry (submitted for publication).

Wang X, Yao S, Kirkpatrick B, Shi C, Yi J. Psychopathology and neuropsychological impairments in deficit and nondeficit schizophrenia of Chinese origin. Psychiatry Research, in press.

Weiden P, Buckley PF. Switching antipsychotic medications. Journal of Clinical Psychiatry (2007, in press).

Weiden PF, Buckley PF, Crody M, Evans D, Understanding and treating first episode schizophrenia. In: Schizophrenia: a complex disorder necessitating comprehensive care. Buckley PF, Messias E (editors) Psychiatric Clinics of North America (2007; in press).

Welham J, Kirkpatrick B, Chant D, Castle D, Saha S, McGrath J. No association between the deficit syndrome in psychosis and summer birth in a Southern Hemisphere country. Australian and New Zealand Journal of Psychiatry 2006 Oct;40(10):935-6.

Wonodi I, Mitchell BD, Stine OC, Hong LE, Elliott A, Kirkpatrick B, Carpenter WT Jr, Thaker GK, Buchanan RW. Lack of association between COMT gene and deficit/nondeficit schizophrenia. Behav Brain Funct. 2006 Dec 15;2(1):42.